tailieunhanh - Anti-cancer effect of 131I-nimotuzumab on immune deficiency mouse bearing human larynx cancer

The aim of this study is: To assess the anti-cancer effects of 131I-nimotuzumab on immune deficient mouse bearing human laryngeal cancer. In this study, we used EGFR-specific monoclonal antibody, nimotuzumab in combination with 131I to form 131I-nimotuzumab complex, and evaluated the antitumor activity of this complex in immunocompromised mice xenografted with the human laryngeal cancer line Hep2. This is the initial basis for the development of this complex application for laryngeal cancer treatment in the future. | JOURNAL OF MILITARY PHARMACO-MEDICINE N09-2017 ANTI-CANCER EFFECTS OF 131I-NIMOTUZUMAB ON IMMUNE DEFICIENCY MOUSE BEARING HUMAN LARYNX CANCER Nguyen Thi Kim Huong*; Ho Anh Son**; Nguyen Thi Thu*** Vo Thi Cam Hoa***; Pham Huy Quyen*; Nguyen Linh Toan** SUMMARY 131 Objectives: To assess the anti-cancer effects of I-nimotuzumab on immune deficient mouse bearing human laryngeal cancer. Subjects and methods: Three groups of mice bearing 131 human laryngeal cancers were injected via the tail vein by I-nimotuzumab, nimotuzumab or NaCl, separately. Tumor volume was measured every week. The average survival time 131 and survival rate was calculated for mice in each group. Results: I-nimotuzumab could reducing the tumor volume with extending the average life span and increase the survival rate 131 for the mice. Conclusions: I-nimotuzumab had the highly anti-cancer effects on immune deficient mice bearing human laryngeal cancer. * Keywords: Larynx cancer: 131 I-nimotuzumab; Nude mouse. INTRODUCTION Laryngeal cancer is the second common malignancy in head and neck cancer. Larynx cancer accounts for 2% of all cancer cases [2]. In Vietnam, larynx cancer ranks common second after nasopharyngeal cancer in head and neck cancer and ranks fourth of all types of cancers. This disease is common in men (80%), usually in ages 40 - 60 years, but the current trend is that more young people are affected with growing burden on society and health system [1]. Epidermal growth factor receptor (EGFR) is often overexpressed in larynx cancer with over 90% in head and neck cancer. EGFR signaling plays an important role in the development, progression, invasion, metastasis and angiogenesis in head and neck cancer. In addition, overexpression of EGFR has a poor prognosis of overall survival in patients in Eastern and Western countries. In particular, EGFR expression level is considered to be a predictor of laryngeal squamous cell carcinoma [3]. Currently treatment for head neck cancer and